[WEBINAR] Dealmaking 2026: What’s Changing, What’s Not, and How to Position for the Next Wave

In 2025, biopharma deal activity rebounded sharply, driven by a looming patent cliff and renewed urgency among large pharma to secure de-risked growth. Heading into 2026, the playbook is evolving again, with acquirers increasingly looking beyond single assets toward platforms, differentiated modalities, and ecosystem positioning in high-velocity areas such as oncology, cell and gene therapy, and obesity and cardiometabolic adjacency. At the same time, China’s innovation engine is reshaping global sourcing strategies, accelerating China-to-West licensing and introducing new considerations around diligence, development strategy, and geopolitical risk.

In this webinar, Ipsos will frame the latest dealmaking trends using recent transactions and market data, followed by a moderated discussion with active investors on what is changing in valuation, deal structures, and decision criteria, and what this means for pharma acquirers and innovator biotechs preparing for partnering conversations.

Register today

Registering will also ensure you receive a direct link to the recording once published, and notification of future events or Ipsos thought leadership on this topic.

Speakers:

• Joel Sandler, PhD, Associate Partner, Ipsos Healthcare Advisory (Co-moderator)
• Linda Pullan, PhD, Founder, Pullan Consulting (Co-moderator)
• Hakan Goker, PhD, Managing Director, M Ventures (Panelist)
• Michael King, Managing Director, Equity Research, Rodman & Renshaw (Panelist)